Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""hydrazines"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 5344
Tytuł:
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
Autorzy:
Mittal K; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Cooper GW; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Lee BP; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Su Y; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Skinner KT; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Shim J; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Jonus HC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Kim WJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Doshi M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Almanza D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Kynnap BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Christie AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yang X; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Cowley GS; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Morton CL; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Dwivedi B; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Lawrence T; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Rupji M; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Keskula P; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Meyer S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Clinton CM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bhasin M; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Crompton BD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tseng YY; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Boehm JS; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Ligon KL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Root DE; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Murphy AJ; Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Merck & Co., Rahway, NJ, USA.
Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Spangle JM; Winship Cancer Institute, Emory University, Atlanta, GA, USA.; Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Rivera MN; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Mullen EA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Stegmaier K; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Goldsmith KC; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. william_.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. william_.
Hong AL; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. .; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. .; Winship Cancer Institute, Emory University, Atlanta, GA, USA. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2024 Apr 08; Vol. 7 (1), pp. 426. Date of Electronic Publication: 2024 Apr 08.
Typ publikacji:
Journal Article
MeSH Terms:
Wilms Tumor*/drug therapy
Wilms Tumor*/genetics
Kidney Neoplasms*/drug therapy
Kidney Neoplasms*/genetics
Hydrazines*
Triazoles*
Humans ; Exportin 1 Protein ; Active Transport, Cell Nucleus ; Karyopherins/genetics ; Karyopherins/metabolism ; Receptors, Cytoplasmic and Nuclear/genetics ; Receptors, Cytoplasmic and Nuclear/metabolism ; Cell Line, Tumor ; Apoptosis ; Neoplasm Recurrence, Local ; Doxorubicin/pharmacology ; ATPases Associated with Diverse Cellular Activities/metabolism ; Cell Cycle Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
Autorzy:
Zhang Y; Department of Hematology, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China.
Li J; Department of Oncology and Hematology, Liuyang Hospital of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410300, Hunan, China.
Li X; Department of Nephrology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China.
Geng Q; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China.
Xie Y; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China.
Zhang G; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China.
Wei M; Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China. .
Ma Y; Department of Hematology, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, 046000, Shanxi, China. .
Pokaż więcej
Źródło:
Systematic reviews [Syst Rev] 2024 Apr 04; Vol. 13 (1), pp. 101. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Immunosuppressive Agents*/therapeutic use
Anemia, Aplastic*/drug therapy
Anemia, Aplastic*/epidemiology
Hydrazines*
Pyrazoles*
Humans ; Immunosuppression Therapy ; Benzoates/therapeutic use ; Pathologic Complete Response ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Perturbation of Copper Homeostasis Sensitizes Cancer Cells to Elevated Temperature.
Autorzy:
Scutigliani EM; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
van Hattum J; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.; Department of Urology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Lobo-Cerna F; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Kruyswijk J; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Myrcha M; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Dekkers FEGA; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Hoebe RA; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Edwards F; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Oppelaar JJ; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Amsterdam Cardiovascular Sciences, Microcirculation, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Vogt L; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Amsterdam Cardiovascular Sciences, Microcirculation, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Bootsma S; Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, The Netherlands.
Bijlsma MF; Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Cancer Biology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, The Netherlands.
Picavet DI; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Crezee J; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.; Department of Radiation Oncology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Oddens JR; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.; Department of Urology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
de Reijke TM; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.; Department of Urology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Krawczyk PM; Department of Medical Biology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 28; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 28.
Typ publikacji:
Journal Article
MeSH Terms:
Copper*
Neoplasms*/drug therapy
Hydrazines*
Animals ; Temperature ; Fever ; Hyperthermia
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
Autorzy:
Chang H; West China Hospital of Sichuan University, Chengdu, China.
He G; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
Fu R; Tianjin Medical University General Hospital, Tianjin, China.
Li F; The First Affiliated Hospital of Nanchang University, Nanchang, China.
Han B; Peking Union Medical College Hospital, Beijing, China.
Li T; Novartis Pharma Co., Ltd., Beijing, China.
Liu L; Novartis Pharma Co., Ltd., Beijing, China.
Mittal H; Novartis Healthcare Private Limited, Hyderabad, India.
Jin H; Novartis Pharma Co., Ltd., Beijing, China.
Zhang F; Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 02; Vol. 13 (1), pp. 18955. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Anemia, Aplastic*/drug therapy
Benzoates*/therapeutic use
Hydrazines*/therapeutic use
Adult ; Humans ; East Asian People ; Immunosuppressive Agents ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
New Thiosemicarbazide Derivatives with Multidirectional Biological Action.
Autorzy:
Lasek P; Doctoral School, Medical University of Lublin, Chodzki 7, 20-093 Lublin, Poland.
Kosikowska U; Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Medical University, 20-093 Lublin, Poland.
Kołodziej P; Department of Biology and Genetics, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland.
Kubiak-Tomaszewska G; Department of Biochemistry, Medical University of Warsaw, 02-097 Warszawa, Poland.
Krzyżanowska N; Department of Biology and Genetics, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland.
Szostek T; Department of Biochemistry, Medical University of Warsaw, 02-097 Warszawa, Poland.
Struga M; Department of Biochemistry, Medical University of Warsaw, 02-097 Warszawa, Poland.
Feldo M; Department of Vascular Surgery, Medical University of Lublin, Staszica 11 St., 20-081 Lublin, Poland.
Bogucka-Kocka A; Department of Biology and Genetics, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland.
Wujec M; Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Mar 29; Vol. 29 (7). Date of Electronic Publication: 2024 Mar 29.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Bacterial Agents*/pharmacology
Antinematodal Agents*
Semicarbazides*
Cell Line ; Hydrazines
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ultrasound promoted green synthesis, anticancer evaluation, and molecular docking studies of hydrazines: a pilot trial.
Autorzy:
Ali A; Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Ali A; Department of Pharmacognosy, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Tahir A; Department of Pharmacology, Raghukul College of Pharmacy, Bhopal, India.
Bakht MA; Department of Chemistry, College of Science and Humanity Studies, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Ahsan MJ; Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Jaipur, India.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 135-144.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Design*
Molecular Docking Simulation*
Ultrasonic Waves*
Antineoplastic Agents/*pharmacology
Hydrazines/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Glycerol/chemistry ; Humans ; Hydrazines/chemical synthesis ; Hydrazines/chemistry ; Molecular Structure ; Structure-Activity Relationship ; Water/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Design, Synthesis, and In Vitro and In Vivo Bioactivity Studies of Hydrazide-Hydrazones of 2,4-Dihydroxybenzoic Acid.
Autorzy:
Popiołek Ł; Chair and Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki Street, 20-093 Lublin, Poland.
Gawrońska-Grzywacz M; Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Street, 20-090 Lublin, Poland.
Dziduch A; Chair and Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki Street, 20-093 Lublin, Poland.
Biernasiuk A; Chair and Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Medical University of Lublin, 1 Chodźki Street, 20-093 Lublin, Poland.
Piątkowska-Chmiel I; Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Street, 20-090 Lublin, Poland.
Herbet M; Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8B Jaczewskiego Street, 20-090 Lublin, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 14; Vol. 24 (24). Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article
MeSH Terms:
Hydrazones*/pharmacology
Antineoplastic Agents*/chemistry
Animals ; Humans ; Hydrazines/pharmacology ; Hydrazines/chemistry ; HEK293 Cells ; Zebrafish ; Structure-Activity Relationship ; Microbial Sensitivity Tests
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Autorzy:
Yang F; Nanjing First Hospital, Nanjing Medical University, Nanjing, Chinaand.
Zong H; Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Li F; Nanjing First Hospital, Nanjing Medical University, Nanjing, Chinaand.
Luo S; Nanjing First Hospital, Nanjing Medical University, Nanjing, Chinaand.
Zhang X; Nanjing First Hospital, Nanjing Medical University, Nanjing, Chinaand.
Xu Y; Nanjing First Hospital, Nanjing Medical University, Nanjing, Chinaand.
Zhang X; Nanjing First Hospital, Nanjing Medical University, Nanjing, Chinaand.
Pokaż więcej
Źródło:
Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2135694. Date of Electronic Publication: 2022 Oct 25.
Typ publikacji:
Journal Article
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/drug therapy
Thrombocytopenia*/chemically induced
Humans ; Monocytes ; Receptors, Thrombopoietin/agonists ; Interleukin-4 ; Hydrazines/pharmacology ; Hydrazines/therapeutic use ; Benzoates/pharmacology ; Benzoates/therapeutic use ; Thrombopoietin ; Phenotype ; Macrophages ; Recombinant Fusion Proteins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Indirect hyperbilirubinemia because of eltrombopag in two cases after autologous hematopoetic stem cell transplantation.
Autorzy:
Gunduz BO; Department of Pediatrics, University of Health, Gulhane Training and Research Hospital, Pediatrics, Ankara, Turkey.
Atas E
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Jan 01; Vol. 19 (Suppl 2), pp. S970-S972. Date of Electronic Publication: 2023 Apr 30.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Thrombocytopenia*
Benzoates*
Hydrazines*
Pyrazoles*
Humans ; Stem Cell Transplantation/adverse effects ; Transplantation, Autologous ; Hyperbilirubinemia/therapy ; Hyperbilirubinemia/complications ; Bilirubin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Highly potent inhibitors of cathepsin K with a differently positioned cyanohydrazide warhead: structural analysis of binding mode to mature and zymogen-like enzymes.
Autorzy:
Benýšek J; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.; First Faculty of Medicine, Charles University, Prague, Czech Republic.
Buša M; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.; Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.
Rubešová P; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Fanfrlík J; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Lepšík M; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Brynda J; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Matoušková Z; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Bartz U; Department of Natural Sciences, University of Applied Sciences Bonn-Rhein-Sieg, Rheinbach, Germany.
Horn M; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Gütschow M; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, Germany.
Mareš M; Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 515-526.
Typ publikacji:
Journal Article
MeSH Terms:
Cathepsin K/*antagonists & inhibitors
Hydrazines/*pharmacology
Nitriles/*pharmacology
Protease Inhibitors/*pharmacology
Cathepsin K/metabolism ; Dose-Response Relationship, Drug ; Humans ; Hydrazines/chemistry ; Models, Molecular ; Molecular Structure ; Nitriles/chemistry ; Protease Inhibitors/chemistry ; Structure-Activity Relationship ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor.
Autorzy:
Gordan LN; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Ray D; Karyopharm Therapeutics Inc., Newton, MA 02459, USA.
Ijioma SC; Karyopharm Therapeutics Inc., Newton, MA 02459, USA.
Dranitsaris G; Department of Public Health, Syracuse University, Syracuse, NY 13244, USA.
Warner A; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Heritage T; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Fink M; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Wenk D; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Chadwick P; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Khrystolubova N; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Peles S; Florida Cancer Specialists and Research Institute, Tampa, FL 33609, USA.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jan 14; Vol. 31 (1), pp. 501-510. Date of Electronic Publication: 2024 Jan 14.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Humans ; Hydrazines/therapeutic use ; Triazoles/therapeutic use ; Duration of Therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Investigating the self-assembling of nicotinic hydrazide-based amphiphile into nano-range vesicles and its amphotericin B loading applications.
Autorzy:
Hussain K; H.E.J. Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, Karachi University, Karachi, Pakistan.
Jabbar A; H.E.J. Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, Karachi University, Karachi, Pakistan.
Ali Hasan K; Molecular Biology & Structural Biochemistry Research Laboratory, Department of Biochemistry, University of Karachi, Karachi, Pakistan.
Ali M; H.E.J. Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, Karachi University, Karachi, Pakistan.
Ul-Haq Z; H.E.J. Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, Karachi University, Karachi, Pakistan.
Shah MR; H.E.J. Research Institute of Chemistry, International Centre for Chemical and Biological Sciences, Karachi University, Karachi, Pakistan.
Ahmad Khan S; Department of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan.; Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Rashid MA; Pharmacy Discipline, Faculty of Health, School of Clinical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.; Department of Pharmaceutics, College of Pharmacy, King Khalid University, Guraiger, Abha, Saudi Arabia.
Kazi M; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Abbas MN; Department of Pharmacy, Kohat University of Science and Technology, Kohat, Khyber Pakhtunkhwa, Pakistan.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2023 Dec; Vol. 30 (1), pp. 2174205.
Typ publikacji:
Journal Article
MeSH Terms:
Liposomes*/chemistry
Amphotericin B*/pharmacology
Mice ; Animals ; Hemolysis ; Surface-Active Agents/chemistry ; Hydrazines
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Analysis of clinical characteristics and treatment efficacy in two pediatric cases of ANKRD26 -related thrombocytopenia.
Autorzy:
Pang C; Department of Pediatrics, The Sixth Affiliated Hospital of Guangxi Medical University: The First People's Hospital of Yulin, Yulin, Guangxi, P.R. China.
Wu X; Department of Pediatrics, Red Cross Hospital of Yulin city, Yulin, Guangxi, P.R. China.
Nikuze L; Private practitioner, Pediatric, Bujumbura, Burundi.
Wei H; Department of Pediatrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P.R. China.
Pokaż więcej
Źródło:
Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2262607. Date of Electronic Publication: 2023 Oct 18.
Typ publikacji:
Journal Article
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/diagnosis
Purpura, Thrombocytopenic, Idiopathic*/genetics
Purpura, Thrombocytopenic, Idiopathic*/therapy
Thrombocytopenia*/etiology
Thrombocytopenia*/genetics
Humans ; Infant ; Benzoates/therapeutic use ; Hydrazines/therapeutic use ; Intercellular Signaling Peptides and Proteins/genetics ; Mutation ; Treatment Outcome
SCR Disease Name:
Thrombocytopenia chromosome breakage
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Autorzy:
Barlassina A; Patient-Centered Outcomes and Patient Engagement, OPEN Health Evidence & Access, Marlow, United Kingdom.
González-López TJ; Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.
Cooper N; Department of Immunology and Inflammation, Imperial College London, London, UK.
Zaja F; Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi, Trieste, Italy.; UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
Pokaż więcej
Źródło:
Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2170999. Date of Electronic Publication: 2023 Feb 21.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/etiology
Thrombocytopenia*/etiology
Humans ; Receptors, Thrombopoietin/agonists ; Thrombopoietin ; Receptors, Fc ; Benzoates ; Hydrazines ; Recombinant Fusion Proteins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy.
Autorzy:
Palumbo G; Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Farruggia P; Paediatric Hematology and Oncology Unit, Oncology Department, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy.
Ramenghi U; Department of Pediatric and Public Health Sciences, University of Turin, Regina Margherita Children's Hospital, Turin, Italy.
Russo G; Clinical and Experimental Medicine, University of Catania, Catania, Italy.; Pediatric Hemato-Oncology Unit, Azienda Policlinico Vittorio Emanuele, Catania, Italy.
Borchiellini A; RRC Thrombosis & Haemophilia Centre, AOU Città della Salute e della Scienza - Molinette Hospital, Turin, Italy.
Spinelli M; Pediatric Hematology Oncology Unit, MBBM Foundation, San Gerardo Hospital, Monza, Italy.
Dufour C; Hematology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Giona F; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Ladogana S; Department of Pediatrics, Hemato-Oncology Unit, 'Casa Sollievo della Sofferenza' Hospital, San Giovanni Rotondo, Italy.
Zecca M; Department of Pediatric Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Perrotta S; 'Luigi Vanvitelli' University, Napoli, Italy.
Pession A; AOU S. Orsola Bologna, Italy.
Giordano P; Interdisciplinary department of Medicine, Pediatric Unit, University 'A.Moro' of Bari, Bari, Italy.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2210906.
Typ publikacji:
Journal Article
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/drug therapy
Thrombocytopenia*/chemically induced
Adult ; Humans ; Child ; Benzoates/adverse effects ; Hydrazines/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Autorzy:
Uddin MH; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Al-Hallak MN; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Khan HY; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Aboukameel A; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Li Y; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Bannoura SF; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Dyson G; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Kim S; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Mzannar Y; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Azar I; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Odisho T; Detroit Medical Center, Detroit, Michigan, USA.
Mohamed A; UH Seidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.
Landesman Y; Karyopharm Therapeutics Inc., Newton, Massachusetts, USA.
Kim S; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Beydoun R; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.; Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Mohammad RM; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Philip PA; Henry Ford Cancer Institute, Detroit, Michigan, USA.
Shields AF; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Azmi AS; Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Dec; Vol. 13 (12), pp. e1513.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Carcinoma, Pancreatic Ductal*/drug therapy
Exportin 1 Protein*/antagonists & inhibitors
Drug Combinations*
Animals ; Mice ; Disease Models, Animal ; Gemcitabine/administration & dosage ; Paclitaxel/administration & dosage ; Hydrazines/administration & dosage ; Triazoles/administration & dosage ; Tumor Microenvironment ; Single-Cell Gene Expression Analysis ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).
Autorzy:
Gerard Jansen AJ; Department of Haematology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
McDonald V; Department of Clinical Haematology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Newland A; Academic Haematology Unit, Blizzard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary Institute of London, London, UK.
Morgan M; ITP Support Association, Bolnhurst, UK.
Bastiaanse M; Sobi, Amsterdam, Netherlands.
Wilson K; Sobi, Stockholm, Sweden.
Eriksson D; Sobi, Stockholm, Sweden.
Geldman E; Wickenstones Ltd, Abingdon, UK.
Daykin-Pont O; Wickenstones Ltd, Abingdon, UK.
Prince S; Wickenstones Ltd, Abingdon, UK.
Zwaginga JJ; Department of Haematology, Leiden University Medical Centre, Leiden, Netherlands.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2267942. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Journal Article
MeSH Terms:
Purpura, Thrombocytopenic, Idiopathic*/drug therapy
Thrombocytopenia*
Female ; Humans ; Male ; Middle Aged ; Benzoates/therapeutic use ; Hydrazines/therapeutic use ; Netherlands ; Patient Preference ; Quality of Life ; Receptors, Fc/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Thrombopoietin/metabolism ; Thrombopoietin/therapeutic use ; Young Adult ; Adult ; Aged ; Aged, 80 and over
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar.
Autorzy:
Al-Mashdali AF; National Center for Cancer Care and Research, Department of Oncology, Hematology and BMT Section, Hamad Medical Corporation, Doha, Qatar.
Gulied A; National Center for Cancer Care and Research, Department of Oncology, Hematology and BMT Section, Hamad Medical Corporation, Doha, Qatar.
Bakr MM; National Center for Cancer Care and Research, Department of Oncology, Hematology and BMT Section, Hamad Medical Corporation, Doha, Qatar.
Yassin MA; National Center for Cancer Care and Research, Department of Oncology, Hematology and BMT Section, Hamad Medical Corporation, Doha, Qatar.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2280872. Date of Electronic Publication: 2023 Nov 14.
Typ publikacji:
Journal Article
MeSH Terms:
Thrombocytopenia*/drug therapy
Thrombocytopenia*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Qatar ; Receptors, Fc/therapeutic use ; Thrombopoietin/adverse effects ; Recombinant Fusion Proteins/adverse effects ; Benzoates/adverse effects ; Hydrazines/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 5344

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies